| 摘要 |
Use of cationic amino acid I-lysine and/or oligo-lysine (both I- and d- isomer) (most preferably upto molecular wieght 1000) and/or lysine (both I- and d-) analogues (R- group elongated upto C-12) either alone or in various combinations thereof as biocompatible, potent adjuvant wound healing agents for the treatment of protracted wounds (chronic) as well as acute wounds including leprotic ulcer, longstanding diabetic foot ulcer, decubitus ulcer, etc...and including other clinical conditions, e.g. ischaemic myocardium, and cerebral tissue as well as some solid tumors.
|
